Bacillus Calmette-Guerin in the Treatment of Stage T1 Grade 3 Transitional Cell Carcinoma of the Bladder: Long-term Results

The Journal of Urology

Volumn 154, Issue 6, 1995, Pages 2054-2058

  Pansadoro, V ^a   Emiliozzi, P ^a   Defidio, L ^a   Donadio, D ^a   Florio, A ^a   Maurelli, S ^a   Lauretti, S ^a   Sternberg, C N ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CISPLATIN; DOXORUBICIN; METHOTREXATE; MITOMYCIN C; VINBLASTINE;

ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CYSTECTOMY; CYSTITIS; EPIDIDYMITIS; HEMATURIA; HUMAN; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; BLADDER NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; FOLLOW-UP STUDIES; HUMAN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0028855920     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66692-8     Document Type: Article

References (41)

1. Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases.
2. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.
3. The significance of lamina propria invasion on the prognosis of patients with bladder tumors.
4. Radical cystectomy for historical and pathologic T1,N0,M0 (stage A) transitional cell cancer.
5. T1 bladder tumours.
6. Intravesical bacillus Calmette-Guerin in the treatment of superficial transitional cell carcinoma of the bladder.
7. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor?
8. Superficial bladder cancer: progression and recurrence
9. Origin of high-grade superficial bladder cancer.
10. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial
11. The pT1 G3 bladder tumour.
12. Prognostic factors in local surgical treatment of invasive bladder cancer, with special reference to the presence of urothelial dysplasia.
13. Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression
14. Intravesical BCG instillations in patients with carcinoma in situ and pT1 G3 transitional cell carcinoma of the bladder
15. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy.
16. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
17. Comparison of intravesical BCG to radical cystectomy for high grade, T1 transitional cell carcinoma using Markov decision tree analysis
18. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder.
19. The clinicopathological features of metastatic superficial papillary bladder cancer.
20. Bladder carcinoma as a systemic disease.
21. Regional lymph node metastasis from bladder cancer.
22. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2).
23. Radical cystectomy for stages TA, TIS and T1 transitional cell carcinoma of the bladder.
24. Chemotherapy for carcinoma in situ of the bladder.
25. Factors affecting survival in primary superficial bladder cancer.
26. The place of intravesical chemotherapy as defined by results of prospective randomized studies.
27. Intravesical chemotherapy. Treatment selection, techniques, and results.
28. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.
29. Pharmacodynamics of mitomycin C in cultured human bladder tumors.
30. Results of transurethral resection and intravesical doxorubicin prophylaxis in patients with T1G3 bladder cancer.
31. Registry for Urinary Tract Tumors RWTH Aachen (RUTTAC 1985) 7th Jahresbericht
32. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guerin for transitional-cell carcinoma of the bladder.
33. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?
34. BCG therapy alters the progression of superficial bladder cancer.
35. BCG therapy for superficial bladder cancer: a 10-year followup.
36. Prognostic factors in superficial bladder tumors
37. Volume corrected mitotic index (M/V index) in human bladder cancer; relation to histological grade (WHO), clinical stage (UICC) and prognosis.
38. Long-term results of intravesical therapy for superficial bladder cancer.
39. Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer.
40. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.